Ahmad N R, Nagle D
Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Br J Surg. 1997 Oct;84(10):1445-8.
There has been a resurgence of interest in the use of preoperative radiation therapy, with or without chemotherapy, for locally advanced rectal cancer. The purpose of this study was to analyse the time course and pattern of failure for 74 patients with clinical stage T3 or T4 (cT3-4) rectal cancer treated with preoperative radiation therapy for whom long-term follow-up was available.
Seventy-four patients with cT3-4 rectal cancer received a median of 45.0 Gy radiation alone followed by surgery 4-8 weeks later. Median follow-up was 90 months; two-thirds of patients were followed for at least 60 months.
Following radiation therapy the pathological stage was 4 per cent pT0, 26 per cent pT1-2 and 70 per cent pT3-4. Thirty-two per cent had involved lymph nodes. The actuarial 5-year rates of local control, freedom from distant metastasis and disease-specific survival were 80, 64 and 73 per cent respectively. The corresponding 10-year rates were 73, 51 and 50 per cent. Median times to detection of local and distant recurrence were 34 and 24 months respectively. Eighty per cent of local recurrences were detected within 54 months; 80 per cent of distant recurrences were detected within 57 months.
In this analysis, the time to detection of both local and distant recurrences following preoperative radiation therapy for advanced rectal cancer was surprisingly long. Almost 5 years (57 months) of follow-up were required to detect 80 per cent of all failures. The 5-year local control rate of 80 per cent compares favourably with that achieved by more aggressive chemoradiation regimens for fixed cancers; however, the high distant failure rate with radiation therapy alone suggests that adjuvant systemic therapy should be investigated.
对于局部晚期直肠癌,术前放疗联合或不联合化疗的应用再度引起了人们的关注。本研究的目的是分析74例接受术前放疗且有长期随访数据的临床分期为T3或T4(cT3 - 4)直肠癌患者的失败时间进程和模式。
74例cT3 - 4期直肠癌患者接受了中位剂量为45.0 Gy的单纯放疗,4 - 8周后接受手术。中位随访时间为90个月;三分之二的患者随访至少60个月。
放疗后病理分期为pT0占4%,pT1 - 2占26%,pT3 - 4占70%。32%有淋巴结受累。局部控制、无远处转移和疾病特异性生存的5年精算率分别为80%、64%和73%。相应的10年率分别为73%、51%和50%。局部和远处复发的中位检测时间分别为34个月和24个月。80%的局部复发在54个月内被检测到;80%的远处复发在57个月内被检测到。
在本分析中,晚期直肠癌术前放疗后局部和远处复发的检测时间出奇地长。几乎需要5年(57个月)的随访才能检测到80%的所有失败病例。80%的5年局部控制率与针对固定癌症采用更积极的放化疗方案所取得的结果相比具有优势;然而,单纯放疗的高远处失败率表明应研究辅助性全身治疗。